Skip to main content
SpringerLink
Log in

Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Thrombocytopenia is a major side effect of linezolid therapy. However, there are few reports about the risk factors for linezolid-induced thrombocytopenia. Objective The aim of this study is to evaluate the risk factors for thrombocytopenia in patients who undergo linezolid therapy. Setting Aomori Prefectural Central Hospital in Japan, a tertiary 695 beds hospital. Method A retrospective review was performed using the hospital’s medical records. From January 2010 to August 2012, 75 adult patients who received linezolid therapy were enrolled in this study. Main outcome measure Linezolid-induced thrombocytopenia was defined as a decrease in the patient’s platelet count to <10 × 104/μL or a reduction of ≥30 % from their baseline value. Odds ratios (OR) for thrombocytopenia were analyzed using multivariate stepwise logistic regression analysis. Results Thrombocytopenia occurred in 29 patients (38.6 %), seven of whom required platelet transfusions. The patients who developed thrombocytopenia were significantly older, displayed a significantly higher frequency of renal insufficiency, and received linezolid therapy for significantly longer than the patients without thrombocytopenia. Stepwise logistic regression analysis suggested that receiving linezolid therapy for ≥14 days was a significant risk factor for thrombocytopenia [OR 13.3, 95 % confidence interval (CI) 3.2–55.6, p < 0.01], whereas the creatinine clearance rate exhibited a significant negative correlation with the incidence of the condition [OR 0.98, 95 % CI 0.96–0.99, p = 0.037]. The incidence of thrombocytopenia among the patients who demonstrated creatinine clearance rates of <30 mL/min was 60 % (12/20), which was significantly higher than that observed among the patients who displayed creatinine clearance rates of more than 60 mL/min (26.4 %, 9/34, p = 0.014). Conclusion Receiving linezolid therapy for ≥14 days and a low creatinine clearance rate were suggested to be risk factors for linezolid-induced thrombocytopenia. The platelet counts of patients with these risk factors should be closely monitored.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138(2):135–42.

    Article  CAS  PubMed  Google Scholar 

  2. Vallani P, Regazzi M, Marubbi F, Viale P, Pagani P, Cristini F, et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother. 2002;46(3):936–7.

    Article  Google Scholar 

  3. Lovering A, Zhang J, Bannister G, Lankester J, Brown J, Narendra G, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother. 2002;50(1):73–7.

    Article  CAS  PubMed  Google Scholar 

  4. Brier M, Stalker D, Aronoff G, Batts D, Ryan K, O’Grady M, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47(9):2775–80.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Tsuchida T, Tatsumi S, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17(3):382–7.

    Article  CAS  PubMed  Google Scholar 

  6. Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Kobayashi T, Sadoh S, et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother. 2011;17(1):70–5.

    Article  CAS  PubMed  Google Scholar 

  7. De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL, et al. Linezolid induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 2006;42(8):1111–7.

    Article  PubMed  Google Scholar 

  8. Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanism for linezolid induced anemia and thrombocytopenia. Ann Pharmacother. 2003;37(4):517–20.

    Article  PubMed  Google Scholar 

  9. Niwa T, Suzuki A, Sakakibara S, Kasahara S, Yasuda M, Fukao A, et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31(10):2126–33.

    Article  CAS  PubMed  Google Scholar 

  10. National Cancer Institute, Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v4.0. http://www.cancer.gov/. Accessed 10 Feb 2014.

  11. Ikuta S, Tanimura K, Yasui C, Aihara T, Yoshie H, Iida H, et al. Chronic liver diseases increases the risk of linezolid related thrombocytopenia in methicillin-resistant Staphylococcus aureus infected patients after digestive surgery. J Infect Chemother. 2011;17(3):388–91.

    Article  CAS  PubMed  Google Scholar 

  12. Slatter J, Stalker J, Feenstra K, Welshman I, Bruss J, Sams J, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects. Drug Metab Dispos. 2001;29(8):1136–45.

    CAS  PubMed  Google Scholar 

  13. Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents. 2010;36(2):179–81.

    Article  CAS  PubMed  Google Scholar 

  14. Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68(9):2128–33.

    Article  CAS  PubMed  Google Scholar 

  15. Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, et al. Population pharmacokinetic and pharmacodynamics analysis of linezolid and hematologic side effect, thrombocytopenia Japanese patients. J Antimicrob Chemother. 2011;55(5):1867–73.

    Article  CAS  Google Scholar 

  16. Federico P, Pierluigi V, Piergiorgio C, Barbara P, Eleonora Z, Mario F. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67(3):2034–42.

    Google Scholar 

  17. Ishida S, Maeda K, Nishio C, Nakai Y. Risk factors of linezolid associated thrombocytopenia. Jpn J Chemother. 2013;61(1):1–4.

    Google Scholar 

  18. Nimish P, Hillary V, Linda T, Antonio R, Benjamin W, Amanda D, et al. A comparative evaluation of adverse platelet outcomes among veterans affairs patients receiving linezolid or vancomycin. J Antimicrob Chemother. 2012;67(3):727–35.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Kumiko Kudo (Chief Pharmacist, Aomori Prefectural Central Hospital) for her comments on this article.

Funding

None.

Conflicts of interest

There are no conflicts of interest associated with this manuscript.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Aomori Prefectural Central Hospital, Aomori, Japan

    Ryuichi Hirano

  2. Department of Laboratory Medicine and Blood transfusion, Aomori Prefectural Central Hospital, Aomori, Japan

    Yuichi Sakamoto & Naoki Tachibana

  3. Department of General Medicine, Aomori Prefectural Central Hospital, Aomori, Japan

    Motoki Ohnishi

Authors
  1. Ryuichi Hirano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuichi Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoki Tachibana
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Motoki Ohnishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryuichi Hirano.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hirano, R., Sakamoto, Y., Tachibana, N. et al. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients. Int J Clin Pharm 36, 795–799 (2014). https://doi.org/10.1007/s11096-014-9961-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-014-9961-6

Keywords

Search

Navigation